Pleural Disease is an indication for drug development with over 20 pipeline drugs currently active. According to GlobalData, preregistered drugs for Pleural Disease have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Pleural Disease compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pleural Disease overview
Pleural disorders encompass a spectrum of conditions affecting the protective tissue surrounding the lungs and lining the chest cavity. Within this category, three distinct types emerge—namely pleurisy, pleural effusion, and pneumothorax—each with diverse etiologies. Characterized by inflammation of the pleura, pleurisy stands as a primary manifestation. Conversely, pleural effusion and pneumothorax result from factors such as infection, medical conditions, or chest trauma, leading to the accumulation of fluid, pus, blood, or air or other gases within the pleural space. Common symptoms across all types include chest pain, shortness of breath, and coughing. Treatment approaches vary based on the specific disorder and its severity. Neglected, pleural disorders pose severe risks, potentially culminating in lung collapse, shock, or sepsis.
For a complete picture of PTSR and LoA scores for drugs in Pleural Disease, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
